{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:06:21Z","timestamp":1778259981387,"version":"3.51.4"},"reference-count":31,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To investigate the association between medications and herpes zoster (HZ) in patients with rheumatoid arthritis (RA) given biological disease-modifying antirheumatic drugs (bDMARD) or conventional synthetic DMARD in the clinical setting during 5 years using the Registry of Japanese Rheumatoid Arthritis Patients on Biologics for Longterm Safety (REAL) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We calculated the crude incidence rate (IR) of HZ treated with systemic antiviral medications in 1987 patients from the REAL database. To estimate the association between HZ and medications, a nested case control study was performed with 1:5 case-control pairs matched for age, sex, observation start year, and comorbidity (HZ case group, n = 43; control group, n = 214). We calculated OR and 95% CI of the use of bDMARD, methotrexate (MTX), and corticosteroids for the occurrence of HZ using a conditional logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>The median patient age was 60.0 years, female proportion was 81.5%, and median disease duration was 6.0 years. The crude IR (95% CI) of HZ was 6.66 (4.92\u20138.83)\/1000 person-years. The OR (95% CI) of medication use were 2.28 (1.09\u20134.76) for tumor necrosis factor inhibitor (TNFi) and 1.13 (1.03\u20131.23) for oral corticosteroids dosage (per 1 mg prednisolone increment), both of which were significantly elevated. The OR of non-TNFi and MTX usage were not elevated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>TNFi use and higher corticosteroids dosage were significantly associated with HZ in Japanese patients with RA in the clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.161196","type":"journal-article","created":{"date-parts":[[2017,4,16]],"date-time":"2017-04-16T00:10:12Z","timestamp":1492301412000},"page":"988-995","source":"Crossref","is-referenced-by-count":19,"title":["Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study"],"prefix":"10.3899","volume":"44","author":[{"given":"Sayoko","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2017,4,15]]},"reference":[{"key":"2018112909371041000_44.7.988.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2911"},{"key":"2018112909371041000_44.7.988.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21928"},{"key":"2018112909371041000_44.7.988.3","doi-asserted-by":"publisher","DOI":"10.1086\/598331"},{"key":"2018112909371041000_44.7.988.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21812"},{"key":"2018112909371041000_44.7.988.5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/imj.12679","article-title":"Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-\u03b1 inhibitors","volume":"45","author":"Segan","year":"2015","journal-title":"Intern Med J"},{"key":"2018112909371041000_44.7.988.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"2018112909371041000_44.7.988.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"2018112909371041000_44.7.988.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1099"},{"key":"2018112909371041000_44.7.988.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018112909371041000_44.7.988.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"2018112909371041000_44.7.988.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.22808"},{"key":"2018112909371041000_44.7.988.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"2018112909371041000_44.7.988.13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2018112909371041000_44.7.988.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"2018112909371041000_44.7.988.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201108"},{"key":"2018112909371041000_44.7.988.16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2018112909371041000_44.7.988.17","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0162-0"},{"key":"2018112909371041000_44.7.988.18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3109\/14397595.2014.984829","article-title":"Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010","volume":"25","author":"Nakajima","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2018112909371041000_44.7.988.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0406-3"},{"key":"2018112909371041000_44.7.988.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130466"},{"key":"2018112909371041000_44.7.988.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-011-0541-5"},{"key":"2018112909371041000_44.7.988.22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2018112909371041000_44.7.988.23","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909371041000_44.7.988.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101009"},{"key":"2018112909371041000_44.7.988.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2018112909371041000_44.7.988.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"2018112909371041000_44.7.988.27","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Steering Committee . Clinical safety data management: definitions and standards for expedited reporting. ICH harmonised tripartite guideline. 1994. [Internet. Accessed March 22, 2017.] Available from: www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/clinical-safety-data-management-definitions-and-standards-for-expedited-reporting.html"},{"key":"2018112909371041000_44.7.988.28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc B"},{"key":"2018112909371041000_44.7.988.29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22628"},{"key":"2018112909371041000_44.7.988.30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21599"},{"key":"2018112909371041000_44.7.988.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.07.009"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.161196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T15:58:18Z","timestamp":1719158298000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.161196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,15]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.3899\/jrheum.161196"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.161196","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,15]]}}}